Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

124.62 +1.52 (+1.23%)
Streaming Delayed Price Updated: 3:36 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗
Via Chartmill
News headline image
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗
Via Chartmill
Topics Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗
Via Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Via Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
Via Stocktwits
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗
Neurocrine Biosciences exemplifies GARP investing, blending strong earnings growth, solid profitability, and a reasonable stock price within its sector. 
Via Chartmill
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗
Neurocrine Biosciences (NBIX) combines strong growth, high profitability, and a positive technical breakout setup in the neuroscience sector. 
Via Chartmill
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗
Neurocrine (NBIX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗
Discover NBIX, a top momentum stock with accelerating EPS growth of 64.5%, rising profit margins, and a perfect technical rating for a potential breakout. 
Via Chartmill
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results. 
Via Benzinga
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the Affordable Growth Profile ↗
Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and a reasonable valuation, fitting an affordable growth investing strategy. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Neurocrine Biosciences (NBIX) is a strong value stock with a debt-free balance sheet, high profitability, and solid growth, trading at a discount to its industry peers. 
Via Chartmill
News headline image
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100... 
Via Benzinga
Topics Economy Stocks
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Q3 2025 Earnings Top Estimates, Driving Stock Momentum ↗
Neurocrine Biosciences (NBIX) smashed Q3 2025 earnings estimates, with a 26% EPS beat and strong revenue growth driven by its flagship product INGREZZA®. 
Via Chartmill
News headline image
Neurocrine Bio Surges After Crushing Third-Quarter Expectations ↗
Shares of Neurocrine Biosciences raced ahead late Tuesday on better-than-expected third-quarter sales and earnings. 
Via Investor's Business Daily
News headline image
Examining the Future: Neurocrine Biosciences's Earnings Outlook ↗
 
Via Benzinga
News headline image
What 13 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity ↗
Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments. 
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗
Discover Neurocrine Biosciences (NBIX), a neuroscience leader with strong growth, high profitability, and a positive technical breakout setup. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.